StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Pelthos Therapeutics's enterprise value was $10.73M on Nov 11, 2026, against $73.57M a year earlier. Over the last 3 years it ranged from $1.21M to $81.61M, with a median of $12.36M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$10.73M-86.9%
2025Dec 31, 2025$81.61M+3198.1%
2024Dec 31, 2024$2.47M–

More Pelthos Therapeutics figures

See a number that looks wrong?